Webcast of QIAGEN N.V. (NASDAQ: QGEN) Third Quarter 2011 Financial Results Call Set for November 3By Qiagen N.v., PRNE
Thursday, October 6, 2011
VENLO, The Netherlands, October 7, 2011 -
QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) today announced the date for the webcast of its conference call related to the publication of results for the third quarter and first nine months of 2011. The webcast will take place at 9:30 a.m. EST / 15:30 CET on Thursday, November 3, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
What: Webcast of QIAGEN’s conference call for results of the third quarter and first nine months of 2011
When: Thursday, November 3, at 9:30 a.m. EST / 15:30 CET
Where: Webcast is accessible at www.qiagen.com/goto/ConferenceCall
How: Log on to the web at the address above
The corresponding presentation slides will be available for download in the Investor Relations section of QIAGEN’s website at www.qiagen.com/goto/ConferenceCall.
The report on results for the third quarter and first nine months of 2011 will be published on Wednesday, November 2, at approximately 22:00 EST.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products tomolecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN’s assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a “gold standard” in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics.
QIAGEN employs nearly 3,600 people in over 30 locations worldwide. Further information about QIAGEN can be found at www.qiagen.com/.
Dr. Thomas Theuringer
Director Public Relations
Tags: Netherlands, October 7, Qiagen N.v., The Netherlands, Venlo